Serivan17 mg

Serivan 17 mg is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The recommended dose of Serivan 17 mg is 34 mg, taken orally as two 17 mg strength tablets once daily, without titration. Serivan 17 mg can be taken with or without food.

Strong CYP3A4 Inhibitors (e.g., ketoconazole): Reduce Serivan 17 mg dose by one-half. Strong CYP3A4 Inducers: Monitor for reduced efficacy. Increase in Serivan 17 mg dosage may be needed.

Nausea, Constipation, Peripheral edema, Gait disturbance, Hallucination, Confusional state.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis. Analyses of 17 dementia-related psychosis placebo-controlled trials (modal duration of 10 weeks and largely in patients taking atypical antipsychotic drugs) revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in placebo-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Serivan 17 mg is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.QT Interval Prolongation: Serivan 17 mg prolongs the QT interval. The use of Serivan 17 mg should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin). Serivan 17 mg should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval

Store at 20°C to 25°C.

Antiparkinson drugs

The mechanism of action of Serivan 17 mg in the treatment of hallucinations and delusions associated with Parkinson's disease psychosis is unknown. However, the effect of Serivan 17 mg could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT2C receptors.

There are no data on Serivan 17 mg use in pregnant women that would allow assessment of the drug-associated risk of major congenital malformations or miscarriage. There is no information regarding the presence of Serivan 17 mg in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Serivan 17 mg and any potential adverse effects on the breastfed infant from Serivan 17 mg or from the underlying maternal condition.

Pediatric Use: Safety and effectiveness of Serivan 17 mg have not been established in pediatric patients.Geriatric Use: No dose adjustment is required for elderly patients.Renal Impairment: No dosage adjustment for Serivan 17 mg is needed in patients with mild to moderate (CrCL ≥30 mL/min, Cockcroft-Gault) renal impairment.Hepatic Impairment: Use of Serivan 17 mg is not recommended in patients with hepatic impairment. Serivan 17 mg has not been evaluated in this patient population.